Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MALMOREDE vs ARAKODA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Malmorede is a synthetic peptide analog of thymosin alpha 1, acting as a biological response modifier. It enhances T-cell maturation and function, increases interleukin-2 production, and modulates immune response by activating dendritic cells and promoting Th1-type cytokine release.
ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.
Hepatocellular carcinoma (HCC) as an adjunct to transcatheter arterial chemoembolization (TACE) in China,Malignant melanoma (adjuvant therapy, limited approval in certain regions),Non-small cell lung cancer (combination therapy, clinical trials)
Radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection
Initial: 50 mg orally twice daily. Maintenance: 100 mg orally once daily.
400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).
4-6 hours; increased in renal impairment (up to 12-15 hours).
Terminal elimination half-life: approximately 14-16 days (range 12-19 days) in healthy adults; this long half-life is due to extensive tissue distribution and slow release from tissues, providing prophylactic coverage for up to 4 weeks after a single dose.
Primarily metabolized by peptidases in plasma and tissues; not significantly metabolized by hepatic CYP450 enzymes.
Primarily metabolized by CYP2D6 and monoamine oxidase (MAO). Tafenoquine undergoes extensive metabolism including N-dealkylation and oxidation.
Primarily renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites.
Biliary/fecal: ~90% unchanged; renal: <1% unchanged (dose-proportional urinary excretion of tafenoquine is minimal, with most eliminated via feces as unchanged drug and minor metabolites).
80-85% bound, primarily to albumin.
~99.5% bound to human serum albumin (HSA); binding is high and saturable, with unbound fraction slightly increasing at high concentrations.
1.2-1.5 L/kg (30-40 L in 70 kg adult); suggests moderate tissue distribution.
Apparent Vd: ~2000 L (or ~24-30 L/kg based on 70 kg), indicating extensive tissue distribution (concentrated in red blood cells, liver, lungs, and adipose tissue).
Oral: 60-70% (first-pass effect); IM: 90-100%.
Oral: ~100% (absolute bioavailability not formally determined, but absorption is complete with minimal first-pass metabolism; relative bioavailability is high based on AUC and clinical efficacy).
Cr Cl 30-50 m L/min: 50 mg once daily; Cr Cl 15-29 m L/min: 50 mg every 48 hours; Cr Cl <15 m L/min or on dialysis: not recommended.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg once daily; Child-Pugh C: not recommended.
Contraindicated in Child-Pugh Class B or C. Use with caution in mild hepatic impairment (Child-Pugh Class A) with no dose adjustment.
Weight <20 kg: not established; 20-40 kg: 2.5 mg/kg/day divided q12h; >40 kg: adult dosing.
Safety and efficacy not established in pediatric patients (<18 years).
Start at lowest effective dose (25 mg daily) due to increased sensitivity; monitor renal function.
No specific dose adjustment; use with monitoring for renal function due to age-related decline and potential for increased adverse effects.
None
ARAKODA can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD testing must be performed before prescribing due to risk of hemolytic anemia.
May cause injection site reactions, transient fever, and mild fatigue. Caution in patients with autoimmune disorders or severe hepatic impairment. Monitor liver function periodically.
Hemolytic anemia in G6PD-deficient patients (contraindicated in G6PD deficiency without prior testing),Methemoglobinemia (rare, monitor for cyanosis and dyspnea),Psychiatric effects including anxiety, depression, and insomnia,Hepatotoxicity (rare, monitor liver function),Use in pregnancy: not recommended (risk of hemolysis in G6PD-deficient fetus),Lactation: avoid if breastfeeding infant is G6PD deficient
Hypersensitivity to malmorede or any excipients; patients with severe autoimmune diseases such as active lupus erythematosus or multiple sclerosis.
G6PD deficiency (without confirmed normal G6PD activity),Known hypersensitivity to tafenoquine or any 8-aminoquinoline,Use in children <16 years (safety not established),Severe renal impairment (e GFR <30 m L/min),Lactation in infants with G6PD deficiency or unknown G6PD status
Avoid grapefruit, grapefruit juice, Seville oranges, and pomelos due to CYP3A4 inhibition. High-fat meals may reduce absorption; take on an empty stomach (1 hour before or 2 hours after a meal). Limit alcohol intake as it may increase hepatotoxicity risk.
Take with a fatty meal to increase absorption. No specific dietary restrictions. Avoid grapefruit juice as it may alter metabolism.
Malmorede has no reported human data. Animal studies show no teratogenic effects at clinically relevant doses. First trimester: no known risk; Second trimester: no known risk; Third trimester: no known risk. FDA pregnancy category N (not classified).
FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.
Unknown if excreted in human milk. M/P ratio not determined. Use with caution; consider benefits versus potential risks to infant.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in infant; use caution, consider discontinuing breastfeeding.
No dosage adjustment required based on pharmacokinetic changes in pregnancy due to lack of data.
No established dose adjustments; pharmacokinetic changes in pregnancy may require monitoring drug levels and clinical response.
MALMOREDE is a novel oral antineoplastic agent with a complex pharmacokinetic profile; its absorption is significantly affected by gastric p H, so avoid concurrent use of proton pump inhibitors (PPIs) and H2 receptor antagonists. Monitor for QT prolongation; obtain baseline ECG and electrolytes. Hepatic metabolism via CYP3A4 necessitates caution with strong inhibitors/inducers. Dose adjustment required in moderate-severe hepatic impairment.
ARAKODA (tafenoquine) is indicated for radical cure of Plasmodium vivax malaria. Assess G6PD status before prescribing; contraindicated in G6PD-deficient patients due to hemolytic anemia risk. Monitor for methemoglobinemia. Avoid use in pregnancy/lactation. Take with food to enhance absorption.
Take this medication at the same time each day with a full glass of water.,Do not take with grapefruit or grapefruit juice; avoid Seville oranges and pomelos.,Swallow capsules whole; do not crush, chew, or open.,If you miss a dose, skip it if within 12 hours of next dose; do not double up.,Report any new or worsening chest pain, palpitations, or fainting immediately.,Use effective contraception during treatment and for 3 months after last dose.,Avoid alcohol and limit consumption of high-fat meals as they may alter drug absorption.
Take with food to improve absorption.,You must be tested for G6PD deficiency before starting this medication.,Report any signs of anemia, dark urine, or yellowing of eyes/skin.,Avoid use during pregnancy or breastfeeding.,Do not drive if you experience dizziness or blurred vision.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MALMOREDE vs ARAKODA, answered by our medical review team.
MALMOREDE is a Antimalarial that works by Malmorede is a synthetic peptide analog of thymosin alpha 1, acting as a biological response modifier. It enhances T-cell maturation and function, increases interleukin-2 production, and modulates immune response by activating dendritic cells and promoting Th1-type cytokine release.. ARAKODA is a Antimalarial that works by ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MALMOREDE and ARAKODA depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MALMOREDE is: Initial: 50 mg orally twice daily. Maintenance: 100 mg orally once daily.. The standard adult dose of ARAKODA is: 400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MALMOREDE and ARAKODA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MALMOREDE is classified as Category C. Malmorede has no reported human data. Animal studies show no teratogenic effects at clinically relevant doses. First trimester: no known risk; Second trimester: no known risk; Thir. ARAKODA is classified as Category C. FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.